As a physician-scientist, Dr. Kevin Staveley-O'Carroll has acquired a broad experience in basic, clinical and translational research, with extensive knowledge and skill sets in cellular and molecular mechanisms of cancer biology and immunology. His goal is to translate basic research into clinical practice.

Education & Training

Medical School

University of Oklahoma


General Surgery

  • Johns Hopkins University School of Medicine


Surgical Oncology

  • Johns Hopkins University School of Medicine


American Board of Surgery


MU Health Care participates with most major managed care organizations. To find out whether MU Health Care is a participating provider in your insurance plan or network, or for information on co-payments and deductibles, please contact your insurance carrier directly.

In the News

Groundbreaking Gastrointestinal Cancer Surgery Is a Game-Changer for Former Football Player (KRCG)
After Trebek's Announcement, A Glimmer of Hope for a Deadly Disease
Patient Enjoys Farm Life Three Years After Pancreatic Cancer Diagnosis (KRCG)

Academic Information

Hugh E. Stephenson Jr., MD, Chair, Department of Surgery
Director of Ellis Fischel Cancer Center

Research Profile

A cancer surgeon by training, Staveley-O’Carroll has expertise in numerous types of cancer including bladder, liver, pancreatic and esophageal. His research and mentoring activities have been funded by the National Institutes of Health and American Cancer Society, as well as foundations, universities and industry. Staveley-O'Carroll currently is the PI for a phase 2 clinical trial investigating Poly-ICLC in the treatment of solid cancers (NCT02423863). Previously, he served as PI for an investigator-initiated phase 1 trial studying the effects of intra-tumoral injection of Poly-ICLC and adoptively transferred dendritic cells in patients with pancreatic adenocarcinoma (NCT01677962). His ongoing R01 grant is funded by the NIH to elucidate the cellular and molecular mechanisms by which chemotherapeutic agents and nanoparticles, prevent immunotolerance and enhance T cell-mediated immunotherapy. He also serves as a PI on a VA Merit Award investigating the effect of radiofrequency ablation after manipulating the tumor microenvironment in our novel model of murine HCC.

Following multiple leadership positions at other university medical centers, Staveley-O’Carroll joined the MU faculty in 2015. Among his other responsibilities, he leads MU’s Ellis Fischel Cancer Center. The center is already home to many high-caliber specialists; Staveley-O’Carroll is adding to their expertise with a focus on innovative clinical procedures, research and clinical trials.

Staveley-O’Carroll’s active involvement with national and international organizations includes serving as president of the Association for Academic Surgery — the largest organization of academic surgeons in the world — and leading the Society of Clinical Surgery’s membership committee. The author or coauthor of more than 90 peer-reviewed articles and book chapters, he has served as editor for the World Journal of Gastroenterology; the World Journal of Hepatology; and Cancer, Biology and Therapy.

Dr. Kevin Staveley-O’Carroll is the director of Ellis Fischel Cancer Center and Hugh E. Stephenson Jr., MD, Chair of Surgery at the School of Medicine.

Download the Featured Profile

Research Interests

  • Clinical trials
  • Tumor‐induced immunotolerance
  • Liver cancer
  • Pancreatic cancer
  • Immunotherapy
  • Crosstalk of gut microbiome and diet in liver fibrosis and liver cancer
  • Animal tumor models

Areas of Expertise

  • Translational research
  • Immunology
  • Cancer
  • Liver disease